Лучшие больницы для «Tetralogy of Fallot (TOF)» в Дубай, ОАЭ

The total cost of primary TOF repair in India, at a JCI- or NABH-accredited pediatric cardiac center, typically ranges from USD 5,000 to USD 12,000 for straightforward cases in infants and children. This estimate includes cardiothoracic surgery fees, cardiopulmonary bypass, pediatric cardiac ICU care (3–5 days), ward stay (7–11 days), standard medications (del Nido cardioplegia, milrinone, amiodarone if required, furosemide, captopril), and all routine post-operative echocardiography and laboratory investigations. More complex variants — such as TOF with pulmonary atresia requiring a cryopreserved homograft conduit or a bovine jugular vein (Contegra™) conduit — or redo procedures (surgical pulmonary valve replacement) may increase the total to USD 12,000–USD 18,000 depending on conduit cost and extended ICU stay. In the UAE (Dubai or Abu Dhabi), at a JCI- and DHA/DOH-accredited institution such as Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, or Aster Hospital, the equivalent primary TOF repair ranges from USD 14,000 to USD 28,000. The higher cost reflects premium hospital infrastructure, internationally credentialed surgical teams with Western training, luxury patient amenities, and the UAE's higher overall healthcare operational costs. Complex conduit-based repairs or transcatheter pulmonary valve replacement (TPVR) using the Melody™ or SAPIEN XT™ valve (which carry significant device costs of USD 8,000–15,000 for the valve alone) will fall toward the upper end of UAE pricing. GAF Healthcare provides families with fully itemized, all-inclusive package quotes for both destinations prior to travel, with no hidden costs for standard care. India represents a cost saving of 40–60% compared to the UAE for comparable surgical outcomes.

International patients should plan for a minimum total in-country stay of 4 to 6 weeks following TOF repair surgery, and must not attempt international air travel before receiving a formal 'fit-to-fly' clearance letter from the treating congenital cardiologist. The timeline breaks down as follows: the child will spend the first 10–16 days in hospital (3–5 days in the pediatric cardiac ICU followed by 7–11 days on the cardiac ward), subject to an uncomplicated post-operative course. After discharge from the hospital, the patient and family must remain near the treating center for a further 2–4 weeks of outpatient monitoring. During this period, weekly clinic visits are conducted including clinical examination, oxygen saturation measurement, weight monitoring, wound assessment, and echocardiography to confirm stable VSD patch closure, acceptable RVOT gradient, and improving RV function. At the 4-to-6-week mark, the congenital cardiologist performs a final assessment — typically including a repeat echocardiogram and a resting SpO2 check. Fit-to-fly clearance is granted when: (1) there is no hemodynamically significant residual VSD, (2) the RVOT peak gradient is < 30–35 mmHg at rest, (3) oxygen saturation is > 92–94% on room air, (4) there is no active arrhythmia requiring IV management, and (5) the sternal wound is healed. If any of these parameters are outside acceptable limits — for example, if the child required ECMO post-operatively, or has ongoing diuretic-dependent pleural effusions — the stay may be extended to 6–8 weeks or beyond. For patients with TOF/pulmonary atresia or redo surgery, plan conservatively for 6–8 weeks in-country. Patients requiring supplemental oxygen during the flight (for SpO2 < 92%) should notify the airline in advance; GAF Healthcare assists with arranging in-flight oxygen and emergency documentation for the journey.

Tetralogy of Fallot repair is one of the most successful major congenital heart surgeries performed today. At high-volume, JCI-accredited pediatric cardiac centers — including GAF Healthcare's partner hospitals in India and the UAE — the 30-day surgical survival rate for elective primary TOF repair in infants and children is 95–98%, reflecting a mortality risk of 2–5%. For optimal-risk patients (infants 3–6 months, no associated syndromes, favorable pulmonary anatomy), some centers report 30-day survival exceeding 98–99%. Mortality risk is higher in neonates under 2.5 kg (5–10%), patients with TOF/pulmonary atresia with MAPCAs (5–15%), and those undergoing redo surgery. Long-term survival data from landmark cohort studies (including the Toronto Congenital Cardiac Centre for Adults and the Mayo Clinic TOF registry) demonstrate 30-year survival of 85–92% and 40-year survival of approximately 78–85% in patients who underwent complete repair, reflecting the excellent durability of the correction. The majority of patients lead normal, active lives — attending school, participating in sports (with individualized cardiology-guided exercise recommendations), and completing normal pregnancies (with appropriate high-risk obstetric and ACHD cardiology co-management). The most significant long-term challenge is the management of pulmonary regurgitation following transannular patch repair: approximately 10–15% of repaired TOF patients will require a pulmonary valve replacement (surgical or transcatheter) within 15–25 years of initial repair, and virtually all should be followed lifelong by an adult congenital heart disease (ACHD) cardiologist. The availability of transcatheter pulmonary valve replacement (TPVR) with the Melody™ or SAPIEN XT™ valve has substantially reduced the burden of redo open-heart surgery in this population. With consistent lifelong cardiac surveillance and timely reintervention when indicated, the overwhelming majority of TOF patients reach adulthood and lead full, productive lives.